Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Hydrus microstent in open-angle glaucoma: single site 24 month results from the SPECTRUM global hydrus registry

Poster Details

First Author: M. Rękas POLAND

Co Author(s):    K. Lewczuk   J. Jablonska   J. Rudowicz   M. Skok-Fraczkiewicz           

Abstract Details

Purpose:

To determine intraocular pressure (IOP) and hypotensive medication changes after implantation of a dilating Schlemm’s canal scaffold (Hydrus Microstent) in a real-world, single site cohort through a follow-up period of 24 months.

Setting:

The study was conducted at a single site and single surgeon in Warsaw, Poland.

Methods:

Patients had confirmed open-angle glaucoma, and underwent combined phacoemulsification and Hydrus Microstent implantation and followed postoperatively for 24 months. Medication use and IOP measurements with Goldmann applanation tonometry were primary outcome measures. The data encompasses 17 patients who completed follow-up at both 12 and 24 months.

Results:

Seventeen patients aged 76.8±7.2 years with open angle glaucoma were included in the study. Of the patients, 52.9% were hypertensive, and 11.8% were diabetic. Glaucoma diagnoses included primary open-angle glaucoma (16/17), and pseudoexfoliative glaucoma (1/17). The average visual field mean deviation was -5.9±5.1 dB, and the average pattern standard deviation was 4.4±2.9 dB. Mean C/D ratio was 0.72±0.2. Preoperatively, IOP was 16.6±3.2 mmHg on 1.5±0.7 medications. Post-operatively, IOP was stabilized with a highly significant reduction of medications (P<0.0001) through 24 months. (15.8±1.7 mmHg on 0 medications at 12 months; 16.6±2.3 mmHg on 0.2±0.4 mean medications at 24 months.

Conclusions:

Treatment with the Hydrus Microstent significantly reduced medication use through 24 months of follow-up while maintaining stable IOP. No clinically significant safety events were reported.

Financial Disclosure:

NONE

Back to Poster listing